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Screening for genetic variants that predispose individuals or their offspring to disease may be performed at the
general population level or may instead be targeted at the relatives of previously identified carriers. The latter
strategy has come to be known as “cascade genetic screening.” Since the carrier risk of close relatives of known
carriers is generally higher than the population risk, cascade screening is more efficient than population screening,
in the sense that fewer individuals have to be genotyped per detected carrier. The efficacy of cascade screening, as
measured by the overall proportion of carriers detected in a given population, is, however, lower than that of
population-wide screening, and the respective inclusion rates vary according to the population frequency and mode
of inheritance of the predisposing variants. For dominant mutations, we have developed equations that allow the
inclusion rates of cascade screening to be calculated in an iterative fashion, depending upon screening depth and
penetrance. For recessive mutations, we derived only equations for the screening of siblings and the children of
patients. Owing to their mathematical complexity, it was necessary to study more extended screening strategies by
simulation. Cascade screening turned out to result in low inclusion rates (!1%) when aimed at the identification
of heterozygous carriers of rare recessive variants. Considerably higher rates are achievable, however, when screening
is performed to detect covert homozygotes for frequent recessive mutations with reduced penetrance. This situation
is exemplified by hereditary hemochromatosis, for which up to 40% of at-risk individuals may be identifiable
through screening of first- to third-degree relatives of overt carriers (i.e., patients); the efficiency of this screening
strategy was found to be ∼50 times higher than that of population-wide screening. For dominantmutations, inclusion
rates of cascade screening were estimated to be higher than for recessive variants. Thus, some 80% of all carriers
of the factor V Leiden mutation would be detected if screening were to be targeted specifically at first- to third-
degree relatives of patients with venous thrombosis. The relative cost efficiency of cascade as compared with
population-wide screening (i.e., the overall savings in the extra managerial cost of the condition) is also likely to
be higher for dominant than for recessive mutations. This notwithstanding, once screening has become cost-effective
at the population level, it can be expected that cascade screening would only transiently represent an economically
viable option.
Introduction
Genetic screening, defined by the European Society of
Human Genetics (ESHG) as “any kind of test performed
for the systematic early detection or exclusion of a ge-
netic disease, the predisposition or resistance to such a
disease, or to determine whether a person carries a gene
variant which may produce disease in offspring,” is a
central issue in community genetics (ESHG Web site).
The recent determination of the human genome se-
quence (International Human Genome Sequencing Con-
sortium 2001; Venter et al. 2001) should promote re-
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search into the molecular basis of human genetic disease,
and it appears likely that the first practical spin-off from
such endeavors will lie in the sphere of gene diagnostics.
Even in the absence of an understanding of the actual
pathophysiological processes involved, the abundance of
new polymorphisms available for analysis and their as-
sociation with specific human traits should pave the way
for the development of predictive tests for conditions
not hitherto amenable to genetic diagnosis. Two major
goals of genetic screening can be distinguished: First, to
facilitate the early provision of therapeutic or prophy-
lactic measures, it is important to identify (as yet) asymp-
tomatic heterozygotes or homozygotes for mutations
that cause predisposition to late-onset disease. Second,
for many recessive conditions, the goal is to recognize
(asymptomatic) heterozygous carriers to aid the process
of reproductive decision making.
The success of medical screening programs is often
assessed in terms of their acceptance rates—that is, by
the proportion of target individuals who, after appro-
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priate counselling, eventually opt for the test (Bowling
1989, Arveux et al. 1992, Weller et al. 1995). However,
with genetic screening, the potential for emotional, eth-
ical, and moral conflict is exceptionally high, and any
efficiency assessment based exclusively on the level of
client appreciation would be overly narrow. For ex-
ample, programs aimed at the identification of carriers
predisposed to late-onset diseases do not normally pro-
vide ideal preventive options. Only some of those tested
would actually benefit personally from the screening test
result and, even if preventive measures were available,
these measures could have detrimental side effects. On
the other hand, screening programs aimed at carriers of
disease alleles that only manifest in their children often
present the target individuals with a personal dilemma.
In view of this, it appears justified to assess the success
of the educational and testing components of a genetic
screening program separately. Whereas the educational
component can be evaluated simply by determination
of the proportion of target individuals who received
sufficient information to decide whether or not to have
the test, the success of the testing component should be
assessed by its efficacy and efficiency—that is, by the
proportion of carriers detected, both in absolute terms
and in relation to the screening effort.
Two distinct types of genetic-screening strategy have
been proposed. One offers testing to the population at
large; the other targets relatives of carriers previously
identified through the testing of their phenotypes or gen-
otypes. The latter strategy, which has been most inten-
sively assessed for cystic fibrosis (Holloway and Brock
1994; Marteau 1994; Super et al. 1994a, 1994b), is
usually referred to as “cascade screening.” The major
difference between population and cascade screening
lies in the design of the educational component. The
first strategy targets individuals who have equal prior
risks and are largely ignorant about the disease in ques-
tion. By contrast, cascade screening is offered to indi-
viduals with an increased risk who usually already have
some knowledge of the disease. Although cascade-like
strategies are undoubtedly more efficient, they are less
efficacious and have lower inclusion rates than popu-
lation-wide screening—that is, the overall proportion of
carriers detected is smaller.
Since both types of genetic screening possess advan-
tages and disadvantages, their relative merits and de-
merits depend upon many factors, each of which is var-
iably relevant to different diseases and different target
populations. One important issue in this context is the
disease (and carrier) frequency in the population of in-
terest. The disease frequency influences the level of pub-
lic awareness prior to a screening program and, im-
portantly, determines both the efficacy and the efficiency
of the program. Perhaps surprisingly, no comprehensive
formal mathematical treatment of the relative advan-
tages of population versus cascade genetic screening
programs has so far been presented. The present study
represents an attempt to fill that gap. To this end, we
have employed a Poisson-type model of reproduction
in a large outbred population, in order to calculate (i)
the inclusion rates of different cascade screening strat-
egies and (ii) the efficiency of cascade screening as com-
pared to population-wide screening. The theoretical
findings will be applied to different genetic models un-
derlying disease causation or predisposition, and the
practical implications will be discussed for three specific
conditions: cystic fibrosis, hemochromatosis, and factor
V Leiden as a risk factor for venous thrombosis. Al-
though cascade and population screening will be dealt
with as separate entities, in reality the two scenarios are
likely to represent opposite ends of a continuum. Thus,
case-finding in order to identify the entry points for
cascade screening procedures may, in practice, exhibit
some characteristics of a population-based approach,
whereas family-based identification of at-risk individ-
uals is likely to precede—and, therefore, to serve to
initiate—any population-wide searches.
Methods and Results
In the following, we shall refer to a screening strategy
that targets all relatives of a given degree of an affected
individual as “comprehensive cascade screening.” If only
first-degree relatives of carriers are tested that have them-
selves been identified in a previous screening cycle, this
will be referred to as “cascade screening sensu stricto.”
Autosomal Dominant: Heterozygous Carriers of
Mutations with Reduced Penetrance
Let Xn denote the property that a heterozygous carrier
of an autosomal dominant mutation is clinically asymp-
tomatic and has no affected offspring in the immediately
following n generations. Let Yn denote the property that
all siblings of a heterozygous carrier have property Xn.
We shall henceforth assume that Xn and Yn are statis-
tically independent; that is, that the penetrance, w, of
the mutation is the same for all carriers and therefore
does not depend upon the number of affected family
members. Then, for the probability f0 of X0,
f p P(X )p 1 w . (1)0 0
We shall further assume that, in the population of
interest, the number of children per individual follows
a Poisson distribution with parameter l. A carrier has
property Xn if—and only if—he/she is clinically asymp-
tomatic and if all his/her carrier children have property
. Assuming that the population frequency, p, of theXn1
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Table 1
Model Parameters of Cascade Screening for Carriers of Autosomal
Dominant Mutations, with lp 2
w f0 g0 f1 g1 f2 g2 f3 g3
.05 .950 .968 .904 .939 .863 .914 .828 .894
.10 .900 .937 .814 .886 .748 .849 .699 .823
.25 .750 .850 .584 .766 .495 .724 .453 .706
.50 .500 .727 .303 .644 .249 .623 .236 .618
.75 .250 .624 .118 .576 .104 .572 .102 .571
.90 .100 .570 .041 .551 .038 .550 .038 .550
Table 2
Inclusion Rate and Efficiency of Cascade Screening for Autosomal
Dominant Mutations, with lp 2
w R1 E1 R2 E2 R3 E3
Epop at p p
.001 .01 .05
.05 .081 2.1 .180 3.2 .288 5.1 526.3 52.6 10.5
.10 .157 2.1 .327 3.3 .486 5.1 555.6 55.6 11.1
.25 .362 2.3 .634 3.5 .801 4.9 666.7 66.7 13.3
.50 .637 3.0 .883 4.1 .964 5.0 1000.0 100.0 20.0
.75 .844 5.0 .978 6.1 .997 6.5 2000.0 200.0 40.0
.90 .943 11.0 .997 12.1 1.999 12.2 5000.0 500.0 100.0
disease allele is sufficiently small (i.e., ), this im-p ! .05
plies that
l i ( ) l2
 if p P(X )p f 7 7 e 7 f2n n 0 n1i!ip0
l
 (1f )n1p f 7 e , (2)20
since the number of heterozygous children of a hetero-
zygote follows a Poisson distribution with parameter
l/2. Similarly,





q p 7i l1 e (i 1)!
is the probability that the carrier’s parents have i ad-
ditional children ( ), andi  0
i i
i 1 1 fni jz p 7 7 f pi,n n( ) ( ) ( )j 2 2jp0
is the probability that, among these additional children,
all carriers have property Xn. This implies that
(l/2)(1f ) ln2 e  e
g p 7 . (3)n l1 f 1 en
Equations (1), (2), and (3) define a recursive relation-
ship by which fn and gn can be calculated from l and
w. By adopting throughout the following, we shalllp 2
assume that the population of interest is of constant size.
The resulting fn and gn values (table 1) facilitate the as-
sessment of the inclusion rate R for almost any cascade-
screening strategy. This is exemplified below by three
distinct strategies aimed at detecting carrier relatives of
an affected individual in either the same or succeeding
generations.
Strategy 1: Screening of all children and all siblings of
an affected individual.—An asymptomatic heterozygous
carrier has no affected parent and no affected sibs if he/
she has property Y0 and if their carrier parent has prop-
erty X0 (i.e., the mutation is not penetrant). Since these
two properties are statistically independent, the proba-
bility of their combined occurrence is . Therefore,f 7 g0 0
R p 1 f 7 g1 0 0
Strategy 2: Additional screening of all grandchildren,
nieces, nephews and first cousins.—An asymptomatic
carrier has no clinically affected grandparent, no affected
uncles or aunts, and no affected first cousins, if the car-
rier grandparent has property X0 and the carrier parent
has property Y1. Owing to statistical independence,
2R p 1 (1 R ) 7 f 7 g p 1 f 7 g 7 g .2 1 0 1 0 0 1
Strategy 3: Additional screening of all great-grand-
children, grandnieces, grandnephews, and second-de-
gree nieces, nephews, and cousins.—On the basis of
arguments similar to those employed in strategies 1 and
2,
3R p 1 (1 R ) 7 f 7 g p 1 f 7 g 7 g 7 g3 2 0 2 0 0 1 2
and, generally, for screening depth n,
n1
nR p 1 (1 R ) 7 f 7 g p 1 f 7 g .n n1 0 n1 0 i
ip0
Inclusion rates for some representative values of w,
and assuming lp2, are summarized in table 2. Inclusion
rates for generations other than the succeeding ones can
be derived similarly from fn and gn values. For example,
screening of the parents of clinically affected individuals
yields an inclusion rate of ; extension of screening1 f1
to the offspring, siblings, uncles, and aunts of patients
results in an inclusion rate of , etc. It should1 f 7 f 7 g1 0 1
be noted that the inclusion rate is independent of
364 Am. J. Hum. Genet. 69:361–370, 2001
Table 3
Inclusion Rate (R1) of Screening for Homozygotes
for Autosomal Recessive Mutations among First-
Degree Relatives of Patients, with lp 2
w
R1 AT pp
.05 .10 .20 .30 .40 .50
.05 .023 .029 .042 .056 .069 .083
.10 .045 .057 .082 .108 .133 .159
.25 .107 .135 .190 .244 .297 .348
.50 .198 .244 .334 .419 .498 .572
.75 .276 .335 .446 .547 .638 .719
.90 .318 .383 .502 .608 .702 .783
whether the cascade screening is performed comprehen-
sively or sensu stricto.
The efficiency of a genetic-screening strategy can be
assessed by the number, E, of unaffected individuals who
have to be screened for one heterozygous carrier to be
detected. E equals the inverse of the respective carrier
risk and, with strategies as outlined above,ip 1, … , 3
amounts to for those carriers who arei(2  w)/(1 w)
detectable by strategy i but not by strategy . There-i 1
fore, with comprehensive screening of relatives,
n1 iE p (R  R ) 7 (2  w) ,n i i1(1 w) 7 R ip1n
with . If screening is performed strictly in cascadeR p 00
fashion, then target individuals have a carrier risk equal
to that given in strategy 1. Therefore, the efficiency of
cascade screening sensu stricto equals E1 for all screening
depths. The efficiency of screening the whole population
equals
1
E p ,pop 2p 7 (1 w)
provided that p is sufficiently small.
Autosomal Recessive: Homozygotes for Frequent
Mutations with Reduced Penetrance
Homozygotes for an incompletely penetrant recessive
mutation have two carrier parents, and, if the frequency
of the mutation is high, some parents may even be ho-
mozygous themselves. This results in multiple branches
of possible inheritance for the mutation, thereby com-
plicating the efficiency assessment of cascade screening
strategies. In the following, we shall first assume that
the reproductive fitness of overt homozygotes is the same
as that of covert homozygotes or as that of any other
genotype (which is typically the case for late-onset dis-
eases, or for diseases for which therapeutic intervention
is possible). Under these assumptions, and under Hardy-
Weinberg conditions, the probability of the combined
parental genotype is
2 2i ia p p (1 p) , (4)i ( )i
where , 1, or 2 is the number of heterozygous (asip 0
opposed to homozygous) parents. The probability, f0,
that neither parent is clinically affected themselves de-
pends upon i, in that . The probability,2-if p f p (1-w)0 0,i
g0, that a homozygote has no clinically affected siblings
is also a function of i and, by arguments similar to those
intrinsic to equation (3), it follows that
ii lw2 l2 e  e
g p 7 . (5)0,i i l2  w 1 e
The inclusion rate, R1, of screening all siblings and all
children of an affected individual equals 1 minus the
weighted sum of the f0,i and g0,i values; that is,
2
R p 1 a 7 f 7 g1 i 0,i 0,i
ip0
Results obtained for some representative values of p and
w, under the assumption that , are summarized inlp 2
table 3.
The efficiency of screening strategy 1 equals the in-
verse of the homozygosity risk of its target individuals,
which, in turn, depends upon parental genotypes. If the
parental genotypes comprise i heterozygotes and 2 i
homozygotes for the mutation in question, then the ho-
mozygosity risk of an unaffected child equals (1
. If one parent lacks a mutation, the risk is 0.iw)/(2  w)
Probabilities of combined parental genotypes, analogous
to equation (4) but conditional upon the presence of an
unaffected individual and at least one affected parent or
sibling, can be calculated using Bayes’ formula (not
shown). The overall homozygosity risk of target indi-
viduals then equals the average of the parental genotype-
specific risks, weighted by the paternal genotype prob-
abilities. Screening efficiency E1 equals the inverse of this
average risk (table 4, top). Note that, for cascade screen-
ing sensu stricto, the efficiency equals E1 for any screen-
ing depth. The efficiency of screening the whole popu-
lation (table 4, bottom) is calculated as
21 wp
E p .pop 2(1 w)p
Owing to the variable number and structure of mutant
lineages leading to a homozygote, the inclusion rate of
extended cascade screening is difficult to assess analyt-
ically and was therefore evaluated by simulation. To this
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Table 4
Efficiency (E1 and Epop) of Screening for Homozygotes for
Autosomal Recessive Mutations, with lp 2
w
E1 AT p p
.05 .10 .20 .30 .40 .50
.05 7.6 5.9 4.0 3.0 2.4 2.0
.10 8.0 6.2 4.2 3.2 2.5 2.1
.25 9.7 7.5 5.1 3.8 3.0 2.4
.50 14.8 11.5 7.8 5.7 4.3 3.4
.75 30.2 23.5 15.7 11.3 8.4 6.3
.90 76.2 59.5 39.5 28.1 20.5 15.2
Epop AT p p
.05 .10 .20 .30 .40 .50
.05 421.0 105.2 26.3 11.6 6.5 4.2
.10 444.3 111.0 27.7 12.2 6.8 4.3
.25 533.0 133.0 33.0 14.5 8.0 5.0
.50 799.0 199.0 49.0 21.2 11.5 7.0
.75 1597.0 397.0 97.0 41.4 22.0 13.0
.90 3991.0 991.0 241.0 102.1 53.5 31.0
Table 5
Inclusion Rates (R2 and R3) of Screening for Homozygotes for
Autosomal Recessive Mutations, with lp 2
w
R2 AT p p
.05 .10 .20 .30 .40 .50
.05 .035 .056 .102 .155 .211 .271
.10 .068 .106 .190 .279 .369 .457
.25 .159 .241 .397 .540 .660 .758
.50 .285 .409 .613 .763 .863 .926
.75 .387 .532 .744 .871 .941 .976
.90 .439 .590 .798 .909 .964 .987
R3 AT p p
.05 .10 .20 .30 .40 .50
.05 .055 .106 .234 .381 .525 .653
.10 .106 .198 .404 .599 .752 .857
.25 .238 .411 .696 .869 .951 .983
.50 .406 .628 .883 .971 .994 .999
.75 .530 .754 .949 .992 .999 1.999
.90 .588 .805 .967 .996 1.999 1.999
end, an ancestral genealogy was constructed in each run,
conditional upon the presence of a pivotal affected off-
spring. Further offspring were added to each generation,
according to a Poisson model ( ), allowing, how-lp 2
ever, for the presence of at least one child for each an-
cestor of the pivotal homozygote. The inclusion rates of
screening strategies 2 and 3 were then evaluated by
counting the number of successes in 1,000,000 simu-
lation runs per parameter combination (table 5). It
should again be noted that the inclusion rates are the
same for comprehensive cascade screening and for cas-
cade screening sensu stricto.
If the reproductive fitness of an overt homozygote is
lower than that of other genotypes, the inclusion rate of
cascade screening is bound to decrease. If patients have
no children at all (i.e., if the disease state is “biologically
lethal”), then equation (4) has to be replaced by
1 2∗ 2i i 2ia p p (1 p) 7 (1 w) ,i ( )2 i(1 wp)
and , for all i. This implies thatf p f p 10 0,i
2 R  wp1∗ ∗R p 1 a 7 g p  R ,1 i 0,i 11 wpip0
where the last relationship is strict (“!”) if andR ! 11
. Assuming , inclusion rates (table 6) and∗wp 1 0 lp 2 R1
R1 (table 3) are very similar for a wide range of values
of p and w, suggesting that the reproductive fitness of
patients has no substantial influence upon the inclusion
rate of cascade screening strategies.
Autosomal Recessive: Heterozygous Carriers of Rare,
Fully Penetrant Mutations
For rare autosomal recessive diseases, virtually all het-
erozygous carriers represent offspring of matings between
a (clinically unaffected) heterozygote and either a hetero-
zygote or homozygote for the wild-type allele. Under
Hardy-Weinberg conditions, the probabilities of these two
mating types are p and , respectively. Only pairs of1 p
two heterozygotes will have affected children, so that het-
erozygous children of a single heterozygous parent always
lack an affected sibling. The probability that a hetero-
zygous child of two heterozygous parents has no affected
sibling equals g0,2, as defined in formula (5), assuming
. Thus, the proportion R1 of heterozygotes whowp 1
have an affected sibling is calculated as R p 11
. This implies that the(p 7 g  1 p)p p 7 (1 g )0,2 0,2
proportion of unaffected carriers who are detectable via
the screening of siblings of patients decreases linearlywith
the disease-allele (and, therefore, carrier) frequency. If
, for example, .lp 2 R p .273 7 p1
Under a Poisson-type model of sibship size, the av-
erage number of siblings of a given individual equals
l
s(l)p  1 .
l1 e
Whereas the average number of heterozygous siblings of
patients is thus , heterozygous first cousins ofs(l) 7 1/2
patients number . Here, is the2 7 s(l) 7 l 7 1/4 2 7 s(l) 7 l
average number of first cousins, and 1/4 is their individual
carrier risk. The ratio, r1, of the number of heterozygous
first cousins versus heterozygous siblings therefore equals
l. By similar arguments, it follows that for sec-2r p l /22
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Table 6
Inclusion Rate ( ) of Screening for Homozygotes∗R1
for Autosomal Recessive Mutations, Assuming
Biological Lethality of the Overt Homozygous
Genotype, with lp 2
w
AT p p∗R1
.05 .10 .20 .30 .40 .50
.05 .020 .024 .033 .041 .050 .059
.10 .040 .048 .064 .080 .097 .114
.25 .095 .112 .147 .182 .218 .255
.50 .177 .205 .260 .316 .372 .429
.75 .248 .281 .349 .416 .483 .551
.90 .286 .321 .393 .464 .535 .606
ond cousins and, generally, . If , thisn n1r p l /2 lp 2n
implies that for all n; that is, the number of clin-r p 2n
ically unaffected carriers who are first, second, etc. cousins
of patients is always twice that of carrier siblings of
patients.
Discussion
Population-wide genetic screening for disorders for
which a successful therapy exists has been practiced for
many years. For example, newborns in Europe, North
America, Australia, New Zealand, Japan, and many
other countries worldwide are routinely screened for the
presence of phenylketonuria (PKU), an autosomal re-
cessive disorder for which a carefully monitored diet
from an early age provides significant amelioration of
the clinical phenotype (Scriver and Kaufman 2001). Ge-
netic screening for curable conditions is clearly beneficial
and therefore widely accepted, since test results help to
confirm the diagnosis, improve the prognosis, and may
serve to identify individualized treatments. Even at a
birth prevalence as low as that of PKU (1 case per 10,000
live births [Scriver and Kaufman 2001]), the benefits of
population-wide screening accruing to patients outweigh
most ethical and economic concerns, thereby rendering
efficiency and efficacy considerations irrelevant.
Heterozygote Screening for Rare Autosomal Recessive
Diseases: Cystic Fibrosis
For severe diseases lacking a viable therapeutic op-
tion, newborn screening would still be helpful if the
early detection of the condition in question were to
have some benefits that served to improve the quality
of life of both the patients and their families. Auto-
somal recessive diseases falling into this category in-
clude cystic fibrosis (CF), the most frequent severe sin-
gle-gene disorder in North America and northern
Europe (Scotet et al. 2000). For a recessive disease such
as CF, it may also be possible to target genetic screening
at heterozygous carriers prior to reproduction, to either
identify at-risk pregnancies or facilitate alternative re-
productive choices prior to conception (Wildhagen et
al. 1998). However, since selective abortion represents
one possible option in the case of a positive prenatal
diagnosis, carrier screening for severe recessive diseases
is less widely regarded as being ethically acceptable
(Schmidtke 1998). Nevertheless, even with CF, for
which the disease-allele frequency p is ∼1/50 in most
European populations, the inclusion rate of carrier
screening among siblings of patients would only be
0.5%. Extension of screening to first and second cous-
ins would still leave more than 97.5% of clinically un-
affected heterozygous carriers in the population un-
detected.
This result is broadly consistent with previous findings
of Holloway and Brock (1994), who calculated an in-
clusion rate R of 4%–13% for CF. Their estimate of R
is somewhat higher than ours, since it was based upon
a constant sibship size of 2 or 3, an assumption which
would have put insufficient weight upon those hetero-
zygotes who do not reproduce at all. Second, the 1977
data on sibship size in Scotland, as employed by Hol-
loway and Brock (1994), broadly fit a Poisson model,
but with instead of . Furthermore, thelp 2.5 lp 2.0
census only referred to married individuals and excluded
singles, who can be assumed to have had fewer children.
Finally, Holloway and Brock (1994) took heterozygotes
from generations preceding the index patient into ac-
count; these we chose to ignore, since most of the target
individuals would have completed reproduction by the
time of screening. Despite some minor discrepancies, the
conclusions drawn by Holloway and Brock are never-
theless in accord with our own in that, even if cascade
screening were to be offered to relatives of patients suf-
fering from CF (or any other rare recessive disease),
“most carrier couples will not be informed of their risk
status before they have an affected child” (Holloway and
Brock 1994, p. 164). Additionally, the sensitivity of ge-
netic testing for CF carriership varies greatly according
to the mutations screened for and the population offered
the screening; screening of the 70 most common mu-
tations would thus detect ∼90% of CFTR gene lesions
in whites but a much smaller proportion in other ethnic
groups (Girodon-Boulandet et al. 2000).
Screening for Homozygous At-Risk Individuals:
Hemochromatosis
Hereditary hemochromatosis (HH) is one of the most
common autosomal recessive disorders in people of
northern European descent, with or higher inpp .05
many populations (Beutler et al. 2001a). In HH, the
body absorbs an excessive amount of iron from the diet,
which is then deposited in various organs. Most ho-
mozygotes have some degree of pathological iron over-
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load, but it is as yet unclear how many of them become
overtly affected. Whereas some studies suggest that as
many as 50% of homozygotes may display at least one
clinical manifestation (Bradley et al. 1996a, 1996b; Oly-
nyk et al. 1999), others imply much lower penetrance
values (Beutler et al. 2001b). Feder et al. (1996) iden-
tified a genetic change in the HFE gene on chromosome
6 which appears to underlie most cases of HH, and a
genetic test for HFE mutations identifies 190% of at-
risk individuals in the United Kingdom (The U.K. Hae-
mochromatosis Consortium 1997). Regular measure-
ment of transferrin saturation and serum ferritin
concentration can be used to detect acute iron overload
in patients, which can then be treated by phlebotomy.
The possibility of clinical intervention to prevent mor-
bidity and mortality, together with the fact that genetic
testing is only required once in a lifetime, provide good
justification for screening for covert homozygotes or
compound heterozygotes who might develop disease at
a later stage (Allen and Williamson 1999). Inspection of
table 5 ( ) reveals that, at a penetrance ofpp .05 wp
, some 40% of unaffected homozygotes or compound.50
heterozygotes for HFE mutations would be detectable
by screening first to third degree relatives of patients. At
a penetrance of , the inclusion rate would equalwp .25
some 24%. Since, in both cases, the number of people
that have to be tested to identify a single at-risk indi-
vidual is 50 times smaller than with population-wide
screening, cascade screening thus appears to represent
an efficient alternative.
It has been argued that population-wide screening for
hemochromatosis could be cost-effective (Scho¨ffski et al.
2000, Beutler et al. 2001a). Generally, a screening strat-
egy, s, is cost-effective if the overall diagnostic costs,
, are lower than the extra costs aris-2N 7 p 7 R 7 E 7 cs s d
ing from managing—rather than preventing or amelio-
rating—the disease, calculated as . Here2N 7 p 7 R 7 cs m
N denotes the population size, and cd and cm are the
diagnostic and extra managerial costs per person, re-
spectively. Note that, under certain conditions, .c ! 0m
This could occur when a large number of individuals
with a positive screening result obtain expensive treat-
ment that would otherwise only be required by a small
number of them. Depending upon the context in which
cost considerations are being made, cd and cm could in-
clude either economical or emotional costs, or both. In
any case, cost-effectiveness is equivalent to .E 7 c ! cs d m
Given that a particular screening strategy is cost-effec-
tive, then any strategy that is more efficient (i.e., one
with a smaller E value) is also going to be cost-effective.
It thus follows that, if population-wide screening for
hemochromatosis is cost-effective, so is cascade screen-
ing. However, for a strategy, s, to be superior to another
strategy, t, the total savings have to be greater with
strategy s than with strategy t, which is the case if
. Apart from a pro-R 7 (c  E 7 c ) 1 R 7 (c  E 7 c )s m s d t m t d
portionality factor on both sides of the inequality,
for hemochromatosis, so that the criterion ofR p 1pop
higher savings becomes
1 Rsc 1 7 cd mE  R 7 Epop s s
Since is small compared to Epop, we may con-R 7 Es s
clude that, if approximately (orc 1 E 7 c 1 0.6cm pop d m
, if and thus ),c 1 E 7 c 1 0.76c wp .25 R p .24m pop d m s
population-wide screening for hemochromatosis is cost-
effective, but cascade screening is predicted to be even
more cost-effective. However, the current trend in mo-
lecular medicine is such that, for most diseases, cm is
bound to increase, whereas high-throughput genotyping
facilities will serve to reduce cd dramatically. It is there-
fore likely that population-wide genetic screening for
many diseases will become cost-effective in the near fu-
ture, and that diagnostic costs will eventually become
so low that cascade screening will become increasingly
unattractive. With hemochromatosis, for example, for
which can currently be assumed, any re-c 1 E 7 cm pop d
duction in the diagnostic costs per head by 140% (or
24% if ) would render cascade screening lesswp .25
cost-effective than population-wide screening. Further-
more, Rs might be substantially reduced for diseases for
which not all patients are correctly diagnosed. This is
especially true for HH, which appears to be a massively
underdiagnosed condition. Reduction of Rs, however,
renders cascade screening less cost-effective than pop-
ulation-wide screening at even higher diagnostic costs
cd. Finally, cascade screening requires the availability of
an index case, the finding of which can either be through
active search or through the “opportunistic” retrospec-
tive approach of known patients. In any case, an emo-
tional burden is likely to be involved, which would not
arise from population screening. Taking the extra emo-
tional costs pertaining to the index case and their rela-
tives into account could therefore detract further from
the appeal of a cascade-screening strategy.
Autosomal Dominant Mutations Underlying Complex
Disease: Factor V Leiden
Most prominent fatal genetic disorders, such as cancer
and heart disease, are multifactorial in nature. Muta-
tions in many genes and in different combinations are
required to cause one of these complex disorders. The
clinical severity of the phenotype is also likely to depend
upon how the different genetic factors interact with en-
vironmental influences. The efficiency of genetic screen-
ing for a multifactorial disease will thus be critically
dependent upon (i) its etiological complexity and (ii) the
net effect that individual genetic variants have upon the
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disease phenotype. Some disorders will be caused by just
one of many possible disruptions in a particular meta-
bolic or developmental pathway, with each case or fam-
ily in effect representing a separate, high-penetrance
Mendelian disorder. These disorders may appear as if
they are complex, but they are, in fact, caused by private
mutations with strong effects. Population screening is
unlikely to be very efficacious in these cases. The same
applies to disorders at the other end of the complexity
spectrum, which involve many genes of small effect op-
erating in concert in any given case.
This notwithstanding, it can be expected that genetic
variants will represent useful risk predictors for a sub-
stantial proportion of complex diseases and that these
variants will formally segregate in the population as
dominant mutations with age-dependent—and therefore
cross-sectionally reduced—penetrance. A typical exam-
ple of this category of mutation is factor V Leiden, a
GrA transition in the gene (F5) encoding human co-
agulation factor V, leading to an ArgrGln replacement
at codon 506. Factor V Leiden has a frequency of ∼4%
in white populations and represents the single-most-fre-
quent genetic risk factor for venous thrombosis (Cooper
and Krawczak 1997). The odds ratio equals 6, leading
to a percentage attributable risk of 16.7% in the general
population. Although in-depth studies of the economic
implications are lacking, such a high impact upon pop-
ulation health suggests that screening for the factor V
Leiden mutation could be cost-effective.
A comparison between table 2 and tables 3, 4, and 5
reveals that the inclusion rates of cascade screening for
at-risk individuals are higher for dominant than for re-
cessive mutations. With a penetrance of —thewp .25
approximate lifetime risk for venous thrombosis of a fac-
tor V Leiden carrier (Cooper and Krawczak 1997)—
screening of first- to third-degree relatives of affected in-
dividuals allows the detection of almost 80% of covert
carriers in the population (table 2). The cost-efficiency is
also higher than for recessive conditions, since only four
individuals would have to be screened to detect one car-
rier. Furthermore, once population-wide screening has be-
come cost-effective, diagnostic costs would have to drop
by 80% for population screening to become more cost-
effective than cascade screening. At present, the cost-ef-
fectiveness of population-wide screening for factor V
Leiden remains to be determined. It has been shown, how-
ever, that screening of all U.S. women using oral contra-
ceptives for factor V Leiden carriership would involve
costs of 1$100 million per preventable death by venous
thrombosis, attributable to the interaction of the two risk
factors (Creinin et al. 1999). Taking a family history of
venous thromboembolic events was thus advocated as a
better and more cost-effective option. These findings lend
further support to the notion that cascade screening is an
economically more sensible option for dominant—as op-
posed to recessive—conditions, and that cascade screen-
ing may also represent a viable option for complex dis-
ease, if and when high-risk predisposing mutations have
been characterized.
Further Considerations
Throughout the derivation of inclusion rates R and
efficiency values E, we have assumed that reproduction
in the population of interest results from randommating.
If this assumption is violated, some of our conclusions
may be inaccurate. For example, some 55% ofmarriages
in the Pakistani proportion of the U.K. population occur
between first cousins (Darr and Modell 1988). With in-
breeding, the carrier risk of close relatives of carriers for
a disease-predisposing mutation would be markedly in-
creased over that applying in a panmictic population.
This implies that both the efficacy and efficiency of cas-
cade screening are higher under inbreeding than under
random mating, and that cascade screening, even for
heterozygosity for recessive mutations, may be cost-ef-
ficient in some populations or subpopulations.
Similarly, if a population is substantially structured
and comprises genetically distinct strata, or if the effect
of the mutation in question is influenced by other en-
vironmental and/or genetic factors, then both the fre-
quency and the penetrance of a disease-predisposing le-
sion may also vary significantly between different
subpopulations. In addition, since the managerial and
preventive costs could be chosen so as to include emo-
tional (in addition to pecuniary) costs, “economic” pa-
rameters could vary according to social and cultural af-
filiation. Under such circumstances, it would appear
sensible to assess the efficiency and efficacy of a screening
strategy separately for each subpopulation. Thus, for
example, screening for BRCA1 and BRCA2 mutations
predisposing to breast cancer has been shown to be cost-
effective in Ashkenazi Jewish women, among whom the
respective variants have a particularly high prevalence
(Grann et al. 1999).
In the present study, we have confined our analysis to
autosomal gene mutations affecting males and females
at equal rates. A substantial proportion of genetic var-
iants for which screening might be worth considering
would, however, be located on a sex chromosome or in
the mitochondrial genome. Other lesions, such as mu-
tations in the BRCA1 and BRCA2 genes, may specifi-
cally predispose only one gender. Although the basic
concepts developed herein should, in principle, be trans-
ferable to sex-specific penetrance values and/or modes
of inheritance, the analytical treatment of such cases will
be much more complicated than that of autosomal gene
mutations affecting both genders at equal rates. For ex-
ample, the recursive definition of parameters fn and gn
(i.e., the probabilities of patients or carriers absent from
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the progeny of individuals and their siblings), by analogy
with equations (2), (3), and (5), would have to allow
for gender and would have to take the exact sex distri-
bution among an individual’s children into account. As
in the case of autosomal recessive mutations, the efficacy
and efficiency of cascade screening under sex-specific ge-
netic models is therefore more easily assessed by simu-
lation. A simulation study specifically addressing the ef-
ficacy of cascade screening for fragile-X syndrome has
recently revealed that testing first- to third-degree rela-
tives of patients would allow the detection of 12% of
at-risk couples who would otherwise go unnoticed
(Wildhagen et al. 1999). This inclusion rate, which is
intermediate to those of heterozygosity for CF and of
covert homozygosity for hemochromatosis, was deemed
to indicate that cascade screening for fragile X is not
very effective. Since fragile-X syndrome is inherited in a
semidominant fashion, the findings of Wildhagen et al.
(1999) will be relatively independent of the frequency
of the causative mutation and should therefore be ap-
plicable to a wide range of similar conditions.
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